Skip to main content
Explore URMC

menu

ADMET2

Research Question:
Is methylphenidate effective for the treatment of clinically significant apathy (lack of interest or concern for things others find moving or exciting) in participants with Alzheimer's disease?

Basic Study Information

Purpose:
Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a Phase III, placebo-controlled, masked, 6 month, 10-center randomized clinical trial sponsored by National Institute of Aging involving 200 participants with Alzheimer's disease (AD). ADMET 2 is designed to examine the efficacy and safety of methylphenidate as treatment for clinically significant apathy in AD. participants. ADMET 2 will enroll participants from real world settings such as outpatient, nursing home, and assisted living facilities and will examine the effects of methylphenidate on apathy and cognition. ADMET 2 will also conduct careful safety monitoring.

Location: AD-CARE, located in Monroe Community Hospital, 435 East Henrietta Road, Rochester, NY 14620
Study Reference #: 56395

Lead Researcher (Principal Investigator)

Lead Researcher: Anton Porsteinsson

Study Contact Information

Study Coordinator: Susan Salem-Spencer
Phone: (585) 760-6562
Email: susan_salem-spencer@urmc.rochester.edu

Additional Study Details

Study Details:
Participation in the study will include 6 follow-up clinic visits and 3 phone calls after the first visit over a period of about 6 months. The clinic visits will last between 1 to 3 hours and each phone call will last approximately 10 minutes. After the first visit, you will come to the clinic monthly (at 1, 2, 3, 4, 5, and 6 months after you start the study) for study visits.

Number of Visits:  6 to 10
Parking:  Free
Transportation Coverage:  No
Reimbursement:  Yes
Payment Details:  You will receive a $25 payment for each completed clinic visit for your time, travel and inconvenience. Payment will be in the form of a check and will be sent within 4 weeks of completing Follow-up Visit 3 (a total of $100 for the Baseline Visit, Follow-up Visit 1, 2 and 3) and Follow-up Visit 6 (a total of $75 for Follow-up Visit 4, 5 and 6). If you withdraw from the study early, you will be paid only for the completed clinic visits.

Learn More About These Conditions

More information about Alzheimer Disease

More information about Alzheimer's disease

More information about Apathy

Want to participate in this study?

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search